Heart experts say Arcoxia too risky for approval and use

Share this article:
A pair of prominent heart experts said in a published report Thursday that studies of Merck’s COX-2 selective inhibitor Arcoxia revealed risks that make it unacceptable for approval in the US and that the drug poses unacceptable dangers to patients in countries where it is already sold. The concerns were expressed in an interview with Reuters by Dr. Steven Nissen, head of cardiology at the Cleveland Clinic and Dr. Curt Furberg, a professor of public health at Wake Forest University who is a member of the Drug Safety and Risk Management Advisory Committee of the FDA. Nissen and Furberg said patients taking Arcoxia in a large international trial had a higher incidence of edema, elevated blood pressure and congestive heart failure than patients taking the standard treatment, diclofenac. Nissen said, “This is a genie I don’t want to see let out of the bottle,” predicting the FDA will refuse to approve Arcoxia. Furberg added that “all versions of Arcoxia should be taken off the market now,” referring to the 63 nations where Arcoxia is currently approved for use. Merck spokesman Chris Loder told Reuters he disagreed with Nissen’s and Furberg’s assessment of Arcoxia. “The product has been evaluated and re-evaluated by regulators in 63 countries, including the European Union,” Loder said. He added that regulators continue to believe the drug’s benefits outweigh its risks. Merck is currently awaiting FDA approval of Arcoxia, which works through the same mechanism as Vioxx. Arcoxia had global sales of $265 million last year.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.